By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panelists debate the market leadership between Novo Nordisk's Rybelsus and Lilly's Foundayo, with key factors being payer coverage, manufacturing risks, and patient preference between fasting and non-fasting oral medications. The market is currently overvaluing Novo's prescription volume, but Lilly's superior oral delivery mechanism and potential non-inferior efficacy could shift the dynamics.
Risk: The single biggest risk flagged is the potential for Novo's current prescription volume to become a 'sunk-cost trap' if Lilly's small molecule proves non-inferior in efficacy without the 'empty stomach' friction, as highlighted by Gemini.
Opportunity: The single biggest opportunity flagged is the potential for Lilly's Foundayo to gain market share once insurance coverage normalizes, leveraging its superior oral delivery mechanism and no-food-restriction advantage, as discussed by Claude.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Eli Lilly and Novo Nordisk dominate the weight loss drug market with their injectable GLP-1 drugs.
Both players recently won approval for oral formulations, offering patients a new, convenient option.
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have been leaders in an area that's seen explosive demand over the past few years: the weight loss drug market. And growth is far from over. Analysts expect this market to expand to nearly $100 billion by the end of this decade. Novo was the first to enter, with semaglutide. Though this product was initially approved as Ozempic for type 2 diabetes back in 2017, it won the OK as Wegovy for obesity soon afterward. Regulators also gave the nod to Lilly for its tirzepatide, sold as Mounjaro and Zepbound for those indications, respectively.
These products are part of the hot class of drugs known as GLP-1, and they've been the talk of the town worldwide thanks to their ability to help people along the path to weight loss. Though Novo led the market in its early days, last year Lilly slipped ahead with 60% share in the U.S. market. At the time, both companies sold uniquely injectable GLP-1 drugs.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Today, however, a new growth catalyst has emerged, and it's the GLP-1 pill. Both companies recently won approval for their oral drugs, and now the race is on to see which one emerges as the leader. With this in mind, is the following news from Novo a warning for Lilly shareholders? Let's find out.
First, let's take a closer look at the products from both of these market giants. Here, I'm talking about the companies' injectables, which patients self-administer on a weekly basis. Novo sells the classic GLP-1, which targets one hormonal pathway involved in the digestion process. This helps the body's regulation of appetite and blood sugar levels. Lilly's drug, as a dual GIP/GLP-1 receptor agonist, operates in much the same way -- but it stimulates two hormonal pathways.
As mentioned, though Novo entered the market first, Lilly caught up and even surpassed this market giant. One reason may be performance, as Lilly's Zepbound in a head-to-head study delivered superior weight loss than Novo's Wegovy.
As a result, Lilly's revenue has soared. For example, in the recent quarter, Zepbound's revenue climbed 80% to $4 billion, and that helped lift the company's total revenue to nearly $20 billion.
Now, both companies are betting on their oral weight loss drugs to offer a fresh boost to growth -- and these products may confirm which player will take the lead in the quarters to come.
Once again, Novo was first to market, winning approval for oral Wegovy in December. Lilly followed, gaining the nod for Foundayo (known in clinical trials as orforglipron) early last month.
Now, let's consider the latest news from Novo: Doctors wrote about 1.3 million prescriptions for oral Wegovy in the first quarter -- its first quarter of commercialization -- and as a result, the Wegovy brand now has captured 65% of new prescriptions in the U.S. Novo chief executive officer Mike Doustdar, in an interview with CNBC, called this a "turnaround situation."
Meanwhile, Lilly's Foundayo, available since April 9, has treated more than 20,000 patients to date.
Is this a warning sign for shareholders of Lilly? It's important to keep in mind a few points that have given Novo an early advantage. The pharma company was first to win approval, so it's normal that more patients are taking oral Wegovy today than Foundayo. Second, Foundayo's sales right now come from patients paying cash to access it; access through insurance should become available soon, and this is likely to drive growth. Finally, oral Wegovy is a pill formulation of Novo's injectable drug -- a drug that doctors and patients know well. Lilly's Foundayo is a new GLP-1 drug, so it may take a bit more time to introduce both parties to it and win their confidence.
So right now, it's not surprising that Novo's oral Wegovy is a step ahead of the Lilly product -- and I don't see it as decisive regarding which product will dominate. One element that I see as driving patients toward Lilly's Foundayo is the fact that, unlike oral Wegovy, it doesn't come with dietary restrictions. Patients can take it with or without food and drink at any time of day. This makes it a very convenient option, and people opting for pills over injectables probably like convenience.
And I actually think the fact that oral Wegovy's sales are booming might be a positive sign for both companies, as it shows that doctors and patients are very interested in oral formulations. These products could be the next growth driver for both weight loss giants -- demand is strong enough to push more than one player along the path to success.
All of this means I wouldn't see Novo's news as a warning for Lilly shareholders; instead, there's reason to be optimistic about a fresh phase of growth ahead.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $475,926! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,296,608!
Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 9, 2026. *
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Lilly’s valuation is currently decoupled from the execution risks of transitioning from high-margin injectables to a competitive oral market where manufacturing cost-efficiency, not just efficacy, will dictate long-term EBITDA margins."
The article conflates market access with clinical superiority, creating a false binary. While Novo Nordisk’s oral semaglutide (Rybelsus) has a first-mover advantage, Eli Lilly’s orforglipron (Foundayo) is a non-peptide small molecule, which is significantly cheaper to manufacture and lacks the complex cold-chain logistics of injectables. Lilly’s valuation, trading at roughly 50x forward earnings, is priced for perfection; any hiccup in insurance formulary placement or a slower-than-expected ramp-up compared to Novo’s established supply chain could trigger a sharp multiple contraction. Investors are ignoring the margin compression risks inherent in scaling oral manufacturing versus the high-margin, high-moat injectable business that currently sustains these premium valuations.
If orforglipron’s efficacy or safety profile in phase 3 trials underperforms against the established semaglutide backbone, Lilly’s entire 'best-in-class' narrative collapses, regardless of manufacturing cost advantages.
"Novo's early oral Wegovy dominance, with 65% new prescription share, threatens Lilly's GLP-1 market leadership beyond a mere launch timing artifact."
The article breezily dismisses Novo's 1.3 million oral Wegovy prescriptions (65% of new U.S. scripts in Q1) versus Lilly's Foundayo at just 20,000 patients after ~3 weeks as a 'head start,' but this gap signals real momentum for NVO's established semaglutide franchise. Lilly's orforglipron is a novel molecule needing to build doctor trust, unlike Novo's familiar pill version of Wegovy. With LLY's history of supply constraints (e.g., ongoing Mounjaro/Zepbound shortages), Novo could cement oral leadership, eroding LLY's 60% injectable share. Q2 data will be pivotal; current trajectory risks multiple contraction for LLY at 60x forward P/E.
Lilly's Foundayo offers superior convenience with no dietary restrictions, and insurance ramp-up could accelerate adoption, mirroring Zepbound's head-to-head weight loss edge over Wegovy.
"Novo's Q1 oral prescription share is a timing artifact, not a market verdict; the decisive test is insurance penetration over the next 12 months, which the article almost entirely ignores."
The article frames Novo's 1.3M oral Wegovy prescriptions as a warning for Lilly, then walks it back unconvincingly. Here's what matters: Novo captured 65% of *new* oral prescriptions in Q1—but Lilly's Foundayo launched April 9, meaning we're comparing a full quarter to ~3 weeks of data. That's not a market signal; it's a timing artifact. More critically, the article omits insurance coverage dynamics. Novo's oral formulation is a known drug (semaglutide) with established payer relationships; Lilly's Foundayo is entirely new to insurers. Payer formulary decisions typically lag 6-12 months. The real test isn't Q1 prescription share—it's whether Lilly's superior efficacy (dual GIP/GLP-1 mechanism) and no-food-restriction advantage convert once insurance access normalizes. The market is pricing in Lilly dominance; early oral Wegovy share doesn't overturn that thesis yet.
If Novo's first-mover advantage in oral formulations compounds—brand loyalty, patient inertia, payer relationships already locked—Lilly could face a structural market-share ceiling despite superior efficacy, especially if insurance access for Foundayo faces unexpected delays or formulary restrictions.
"Foundayo's durability as a growth driver will depend on broad insurance coverage and patient access, not initial launch metrics."
Today's piece highlights the shift from injectables to oral GLP-1s, a new growth cycle for Novo Nordisk and Lilly. Near-term data look supportive: Novo reported about 1.3 million Wegovy prescriptions in Q1 (first-quarter commercialization) and a 65% share of new prescriptions; Lilly’s Foundayo has started onboarding patients (roughly 20k since April 9). But the article skips the gating factor: payer coverage. Without broad insurance reimbursement and affordable out‑of‑pocket access, pill adoption may stall, constraining long-run demand. Additionally, the GLP-1 class faces continued price pressure, competitive noise, and potential safety/regulatory headwinds as adoption scales. Margin capture will hinge on manufacturing and formulary access.
Foundayo’s insurance coverage could accelerate faster than expected, potentially narrowing Lilly’s disadvantage; Novo’s lead on oral Wegovy might erode if payers demand more aggressive pricing or prefer Wegovy’s formulary position. The move from launch traction to durable growth remains highly uncertain.
"Lilly's non-peptide, no-fasting oral formulation will ultimately cannibalize Novo's first-mover volume due to superior patient compliance."
Claude is right about the timing artifact, but both Claude and Grok miss the primary risk: the 'pill' isn't a commodity. Novo’s oral semaglutide requires strict fasting protocols, whereas orforglipron does not. If Lilly’s small molecule proves non-inferior in efficacy without the 'empty stomach' friction, Novo’s 1.3M scripts are a sunk-cost trap. The market is currently overvaluing Novo’s current prescription volume while ignoring the massive patient-compliance advantage inherent in Lilly’s superior oral delivery mechanism.
"Novo's oral semaglutide adherence is battle-tested; Lilly's orforglipron tolerability and supply risks are unproven."
Gemini fixates on fasting as Lilly's edge, but ignores Rybelsus real-world data: despite empty-stomach dosing, adherence rivals injectables per studies (e.g., 70%+ persistence at 6 months). Orforglipron's phase 2 showed higher GI dropout rates without food buffer; scaling novel manufacturing risks shortages like Lilly's injectables. Novo's franchise moat endures until proven otherwise.
"Real-world adherence data on an established drug doesn't predict trial-to-market adoption for a novel molecule; Lilly's injectable supply issues are orthogonal to oral manufacturing risk."
Grok cites 70%+ Rybelsus persistence, but that's real-world *existing* patients—not comparable to Foundayo's trial dropout rates, which measure tolerability in a controlled setting. The real test: do naive patients choosing between pills prefer empty-stomach friction or not? Grok also conflates manufacturing risk (valid) with market adoption (separate). Lilly's supply constraints on injectables don't predict oral outcomes. That's a category error.
"The decisive risk for Lilly is payer coverage and formulary timing, not fasting friction."
Gemini overemphasizes Lilly's no-fasting edge while neglecting payer dynamics. The real hurdle for Foundayo is formulary access and timing: 6–12 months for insurer coverage, plus potential supply bottlenecks from manufacturing scale. Even if efficacy looks favorable, a slow reimbursement ramp could keep Lilly trading at fragile multiples while Novo's entrenched payer relationships defend its moat. The market should price near-term access risk, not just dose-friction debates.
The panelists debate the market leadership between Novo Nordisk's Rybelsus and Lilly's Foundayo, with key factors being payer coverage, manufacturing risks, and patient preference between fasting and non-fasting oral medications. The market is currently overvaluing Novo's prescription volume, but Lilly's superior oral delivery mechanism and potential non-inferior efficacy could shift the dynamics.
The single biggest opportunity flagged is the potential for Lilly's Foundayo to gain market share once insurance coverage normalizes, leveraging its superior oral delivery mechanism and no-food-restriction advantage, as discussed by Claude.
The single biggest risk flagged is the potential for Novo's current prescription volume to become a 'sunk-cost trap' if Lilly's small molecule proves non-inferior in efficacy without the 'empty stomach' friction, as highlighted by Gemini.